Table 1.
Clinical characteristics of the patients
| All patients | 3 m group | 2 m group | 1 m group | p-value | |
|---|---|---|---|---|---|
| n | 40 | 10 | 10 | 20 | |
| Age | 70.6 ± 7.0 | 73.4 ± 7.9 | 72.1 ± 6.9 | 68.5 ± 6.2 | 0.147 |
| BW (kg) | 64.2 ± 7.9 | 61.7 ± 6.9 | 62.0 ± 8.9 | 66.1 ± 6.8 | 0.289 |
| Height (cm) | 166.6 ± 5.1 | 166.9 ± 3.4 | 164.5 ± 6.2 | 165.9 ± 5.3 | 0.166 |
| BMI | 23.1 ± 2.6 | 22.1 ± 2.3 | 22.9 ± 2.9 | 24.0 ± 2.1 | 0.295 |
| PSA | 12.0 ± 9.9 | 8.91 ± 7.10 | 17.6 ± 14.9 | 10.65 ± 6.84 | 0.177 |
| GS; n (%) | |||||
| 6 | 5 (12) | 2 (20) | 3 (15) | ||
| 7 | 22 (55) | 7 (70) | 4 (40) | 11 (55) | |
| 8 | 8 (20) | 3 (30) | 2 (20) | 3 (15) | |
| 9 | 5 (13) | 2 (20) | 3 (15) | ||
| TNM classification; n (%) | |||||
| T1cN0M0 | 5 (13) | 2 (20) | 3 (15) | ||
| T2N0M0 | 22 (55) | 8 (80) | 4 (40) | 10 (50) | |
| T3N0M0 | 13 (33) | 2 (20) | 4 (40) | 7 (35) | |
| D’Amico risk classification; n (%) | |||||
| low | 2 (7) | 1 (10) | 1 (5) | ||
| intermediate | 12 (40) | 3 (30) | 2 (20) | 7 (35) | |
| poor | 16 (53) | 7 (70) | 7 (70) | 12 (60) | |
Data are presented as means ± SD unless indicated otherwise
BW body weight; BMI Body Mass Index; PSA prostatic specific antigen; GS Gleason score; SD standard deviation